Retreatment with glecaprevir/pibrentasvir and sofosbuvir in patients with viral failure at DAA

Abstract

Introduction and Aim: Development of direct-acting antiviral (DAA) agents revolutionized the treatment of patients with chronic HCV infection and DAAs are currently the standard of care. Combination regimens of DAA agents targeting different viral proteins to halt viral replication are frequently used and often?>?95% of patients achieve SVR 12 weeks post-treatment (SVR12). Nevertheless, a small proportion of patients experience HCV relapse. Various virological factors [HCV genotypes, HCV with resistance associated amino acid substitutions (RAS), advanced liver cirrhosis and/or poor drug adherence) may contribute to cause treatment failure.